ArticleJournal of medicinal chemistry2026
Discovery of Two Structurally Distinct Classes of Inhibitors Targeting the Nuclease MUS81 and Enhancing Efficacy of Chemotherapy in Cancer Cells.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleases are promising pharmacological targets due to their essential role in maintaining genomic stability. They are crucial for regulation of cell viability, and their modulation is exploitable in disease prevention and treatment, including cancer. The conserved structure-specific endonuclease MUS81 resolves branched DNA intermediates during replication, repair, and recombination. Aberrant MUS81 activity causes DNA damage, chromosomal abnormalities, and genome instability, contributing to oncogenesis. Thus, pharmacological targeting of MUS81 is an attractive yet underexplored therapeutic strategy. We describe the discovery of two chemically distinct small-molecule classes of MUS81 inhibitors, exemplified by compounds MU262 and MU876. Both compounds effectively inhibit MUS81 in vitro and in cells, sensitizing cancer cells to DNA-damaging agents by impairing DNA repair. These inhibitors can also serve as chemical biology tools for a deeper study of MUS81 function and as leads for drug discovery aimed at therapies exploiting DNA repair vulnerabilities in cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.